TABLE OF CONTENTS

Chapters **Page Nos.**

Acknowledgements……i

List of Figures……v

List of Tables……..…viii

List of Abbreviations……..x

Abstract……xii

Chapter 1

1. Introduction…….....1

1.1. Metabolic syndrome……1

1.2. Association of Metabolic Syndrome with Female Infertility……..2

1.3. Polycystic Ovary Syndrome……3

1.3.1. Guidelines for diagnosis of PCOS……...4

1.3.2. Prevalence of PCOS……6

1.4. Ovarian follicular structure and function……6

1.5. Steroid hormones and steroid hormone receptors……...7

1.5.1. Progesterone……7

1.5.2. Androgen ……8

1.5.3. Estrogen……8

1.6. Steroidogenesis……9

1.6.1. Regulation of steroidogenesis……12

1.6.1.1. Steroidogenic Acute Regulatory Protein (StAR)……12

1.6.1.2. 17α-hydroxylase/17, 20 lyase (CYP17A1) ……...……13

1.6.1.3. 3β -Hydroxysteroid Dehydrogenase/Isomerase (3b-HSD)……14

1.6.1.4. P_{450} Aromatase (CYP19A1)……14

1.7. Pathophysiology of PCOS……15

1.7.1. Derangements of the gonadotropin system……16

1.7.2. Hyperinsulinemia and Insulin resistance……17

1.7.3. Hyperandrogenism……18

1.7.4. Ovarian follicular arrest……20

1.7.5. Alteration in steroidogenesis in PCOS……...21
1.8. Models to study PCOS……..22
1.9. PCOS and therapeutic interventions…….26
1.9.1. Diet, Exercise…….26
1.9.2. Drugs……..26
1.9.2.1. Metformin……26
1.9.2.2. Clomiphene Citrate…….27
1.9.2.3. Rosiglitazone……...27
1.9.2.4. Side effects of drugs available for PCOS management……..27
1.9.3. PCOS and herbal therapy……...28
1.10. Aim and hypothesis of the study…….33
1.11. Specific Objectives……..34

Chapter 2

2. Material and methods……35

2.1 Phytochemical Analysis…….36
2.1.1. Plant Material……..…..36
2.1.2. Extraction method……..…37
2.1.3. Preliminary Phytochemical Analysis……...……..38
2.1.3.1. Qualitative Analysis……39
2.1.3.2. Quantitative Analysis of Phytosterols…….41
2.1.4. Isolation of the Phytoconstituents……..42
2.1.4.1. Column Chromatography……42
2.1.5. Gas Chromatography- Mass Spectrometry (GC/MS) analysis……..43
2.1.5.1. Sample preparation…….…44
2.1.5.1.1. Extraction conditions and sample preparation for plant derived matrices for GC/MS analysis…….44
2.1.5.1.2. Extraction conditions and sample preparation for rat derived biological matrices for GC/MS analysis……44
2.1.5.2. Instrumentation……..……..44
2.1.5.3. Identification of phytocomponents……..45
2.1.6. Reverse Phase High Performance Liquid Chromatography (RP-HPLC) analysis…….45
2.1.6.1. Instrumentation……45

2.1.6.2. Preparation of calibration standards and quality control samples……...45

2.1.6.3. Sample Preparation……46

2.1.6.3.1. Extraction conditions and sample preparation for plant derived matrices for RP-HPLC analysis……..46

2.1.6.3.2. Extraction conditions and sample preparation for rat derived biological matrices for RP-HPLC analysis……46

2.1.6.4. Method development for RP-HPLC……47

2.1.6.4.1. Detection of wavelength……...47

2.1.6.4.2. Choice of Stationary Phase……..47

2.1.6.4.3. Selection of the Mobile Phase……..47

2.1.6.4.4. Flow Rate……48

2.1.6.5. Method Validation for the RP-HPLC analysis……48

2.1.6.5.1. Selectivity……48

2.1.6.5.2. Linearity……...48

2.1.6.5.3. Sensitivity……49

2.1.6.5.4. Precision and Accuracy……49

2.1.6.5.5. Extraction Recovery……50

2.2 Pharmacokinetics and tissue distribution study……50

2.2.1. Animals……..50

2.2.2. Pharmacokinetics analysis……50

2.2.3. Pharmacodynamic analysis……51

2.2.4. Analysis of Tissue Distribution……52

2.2.5. Excretion experiment……52

2.3 “In- silico” Analysis and its Validation by Steroidogenesis Modulatory Bioassay……...53

2.3.1. Molecular Docking Study……..53

2.3.2. Ligand Preparation……...53

2.3.3. Retrieval of Target Sequence……54

2.3.4. *“In-silico”* Absorption, Distribution, Metabolism, Elimination and Toxicity (ADMET) Predictions……55

2.3.5. Effect of Isolated Partially Purified Phytocomponents on the Cell Viability of KGN cell-line……56

2.3.6. *“In- vitro”* Steroidogenesis Modulatory Bioassay……....56

2.3.7. Hormone Estimation……..57

2.4. *"In-vitro"* Analysis in PCO-like Ovarian Cellular Models……..……...57
2.4.1. Primary Culture of Rodent-derived Granulosa Luteal Cells……..57
2.4.1.1. Animals……...57
2.4.1.2. Granulosa Luteal Cell Isolation from Rat Ovaries……..58
2.4.1.3. Characterization of Isolated Luteal Cells……58
2.4.2. KGN cell-line……...…..59
2.4.3. Culture and development of PCO- like Ovarian microenvironment……..59
2.4.4. Effect of Hyperandrogenic and Hyperinsulinemic conditions on the Cell Viability….59
2.4.5. Validation of *"in-vitro"* PCO- like model……60
2.4.6. Effect of Isolated Partially Purified Phytocomponents on the *"In-vitro"* PCO-like Model……...60
2.5. *"In-vivo"* Analysis in PCOS Rodent Model……61
2.5.1. Animal Housing and Maintenance……61
2.5.2. PCOS Mouse Model……...61
2.5.3. Drug administration and experimental design……62
2.5.3. Oral Glucose Tolerance Test (OGTT) and HOMA-IR……..64
2.5.4. Lipid Profile……...64
2.5.5. Estrus Cyclicity……..65
2.5.6. Hormone Estimation……..65
2.5.7. Histological Examination of the Ovaries……...65
2.5.8. Estimation of Toxicity Markers……66
2.5.8.1. Alanine aminotransferase (ALT) activity……67
2.5.8.2. Aspartate aminotransferase (AST) activity……68
2.5.8.3. Estimation of Creatinine……..69
2.6. Gene Expression Analysis……70
2.6.1. RNA Isolation……70
2.6.2. Quantification of RNA……..….72
2.6.3. cDNA synthesis……..72
2.6.4. Real-time PCR……73
2.6.5. Real-time PCR data analysis……..74
2.7. Statistical analysis……74

Chapter 3

3. Isolation and characterization of the Non-polar phytocomponents of *Aloe vera* gel and evaluation of the pharmacokinetics, tissue distribution and pharmacodynamics...……76

3.1. Introduction……...76

3.1.1. Classification of *Aloe vera*……76

3.1.2. Vernacular names of *Aloe vera*……..76

3.1.3. Part of use……...76

3.1.4. Distribution of *Aloe vera*……77

3.1.5. Morphology of *Aloe vera*……...77

3.1.6. Traditional Uses of *Aloe vera*……77

3.1.7. Phytochemicals present in *Aloe barbadensis* Mill……78

3.2. Materials and methods……..79

3.3. Results……...80

3.3.1. Phytochemical Analysis……80

3.3.2. Isolation and Characterization of Non-polar Phytochemicals from *Aloe vera* gel……81

3.3.3. Chromatographic analysis……..82

3.3.3.1. Thin layer chromatography (TLC) analysis……82

3.3.3.2. Gas Chromatography- Mass Spectrometry (GC/MS) analysis……...83

3.3.3.3. Reverse Phase- High Performance liquid chromatography (RP-HPLC) analysis…..89

3.3.3.3.1. Method validation for HPLC analysis……..91

3.3.3.3.1.1. Linearity and sensitivity……92

3.3.3.3.1.2. Precision and accuracy……..93

3.3.3.3.1.3. Recovery……94

3.3.4. Pharmacokinetics of Non-polar Phytocomponents of *Aloe vera* gel in rats……...95

3.3.5. Tissue distribution of Non-polar Phytocomponents of *Aloe vera* gel in rats……98

3.3.6. Excretion of Non-polar Phytocomponents of *Aloe vera* gel in rats……100

3.3.5. Pharmacodynamic analysis of Non-polar Phytocomponents of *Aloe vera* gel in rats……..100

3.3.6. Analysis of Toxicity Markers……...101

3.4. Discussion……...102

3.5. Conclusion……...104

Chapter 4

4. Identification of the targets of the isolated phytocomponents of Non-polar fraction of *Aloe vera* Gel Extract using *"in-silico"* approach and its validation...……106

4.1. Rationale of the study……..106

4.2. Materials and methods……107

4.3. Results……108

4.3.1. Effect of PPNPPs isolated from *Aloe vera* gel on the steroidogenic and metabolic targets using *"in-silico"* approach……108

4.3.1.1. Docking Studies of PPNPPs isolated from *Aloe vera* gel……108

4.3.1.2. *"In-silico"* Absorption, Distribution, Metabolism and Excretion (ADME) studies……112

4.3.2. Effect of PPNPPs isolated from *Aloe vera* gel on the steroidogenic and metabolic targets using *"in-vitro"* approach……..115

4.3.2.1. Effect of PPNPPs isolated from *Aloe vera* gel on the KGN cell-line morphology and viability and calculation of IC_{50} value……115

4.3.2.2. Effect of PPNPPs isolated from *Aloe vera* gel on the hormone secretion by KGN cell-line……..117

4.3.2.3. Effect of PPNPPs isolated from *Aloe vera* gel on the gene expression of steroidogenic regulators……118

4.3.2.4. Effect of PPNPPs isolated from *Aloe vera* gel on the gene expression of steroid receptors……120

4.3.2.5. Effect of PPNPPs isolated from *Aloe vera* gel on the gene expression of key metabolic regulator-Insulin receptor……..121

4.4. Discussion……...121

4.5. Conclusion……..124

Chapter 5

5. Role of Isolated Phytocomponents of Non-polar fraction of *Aloe vera* Gel Extract in PCO-like ovarian cellular models...……126

5.1. Rationale of the study……..126

5.2. Materials and methods……128

5.3. Results……129

5.3.1. Development of *"in-vitro"* PCO- like model using rodent derived granulosa luteal cell primary culture……...129

5.3.1.1. Isolation and Characterization of Luteinized Granulosa Cells……129

5.3.1.2. Effect of Hyperinsulinemia on Cell Viability of Luteinized Granulosa Cells……..131

5.3.1.3. Effect of Hyperandrogenemia on Cell Viability of Luteinized Granulosa Cells…..131

5.3.1.4. Synergistic Effect of Hyperinsulinemia and Hyperandrogenemia on Cell Viability and Morphology of Primary Culture of Luteinized Granulosa Cells……132

5.3.1.5. Synergistic Effect of Hyperinsulinemia and Hyperandrogenaemia on the Transcript Levels of Key Steroidogenic Targets in Primary Culture of Luteinized Granulosa Cells….132

5.3.1.6. Synergistic Effect of Hyperinsulinemia and Hyperandrogenaemia on the Hormone Secretion by Primary Culture of Luteinized Granulosa Cells……135

5.3.2. Development of *"in-vitro"* PCO- like model using Human derived KGN cell-line...136

5.3.2.1. Effect of Hyperinsulinemia on Cell Viability of KGN cell-line……...136

5.3.2.2. Effect of Hyperandrogenaemia on Cell Viability of KGN cell-line……136

5.3.2.3. Synergistic Effect of Hyperinsulinemia and Hyperandrogenaemia on Cell Viability and Morphology of KGN cell-line……136

5.3.2.4. Synergistic Effect of Hyperinsulinemia and Hyperandrogenaemia on the Transcript Levels of Key Steroidogenic Targets in KGN cell-line……138

5.3.2.5. Synergistic Effect of Hyperinsulinemia and Hyperandrogenaemia on the Hormone Secretion by KGN cell-line……139

5.3.3. Effect of PPNPPs isolated from *Aloe vera* gel on the steroidogenic targets in an *"in-vitro"* PCO- like model……..140

5.3.3.1. Effect of PPNPPs isolated from *Aloe vera* gel on the Transcript Levels of Key Steroidogenic Targets in an *"in-vitro"* PCO- like model……..140

5.3.3.2. Effect of PPNPPs isolated from *Aloe vera* gel on the Hormone secretion in an *"in-vitro"* PCO- like model……..141

5.4. Discussion……...144

5.5. Conclusion……...148

Chapter 6

6. Role of Isolated Phytocomponents of Non-polar fraction of *Aloe vera* Gel Extract in Letrozole induced PCOS mice model...…….…….149

6.1. Rationale of the study……..149

6.2. Materials and methods……150

6.3. Results……152

6.3.1. Development of Letrozole induced PCOS mouse model…….152

6.3.1.1. Effect of Letrozole on Body Weight…….152

6.3.1.2. Effect of Letrozole on the Hormone Profile……..152

6.3.1.3. Effect of Letrozole on Estrus Cyclicity……..……..153

6.3.1.4. Effect of Letrozole on Ovarian Histology…….154

6.3.2. Effects of Different Treatments on Metabolic parameters……...156

6.3.2.1. Effects of Different Treatments on Body Weight…….156

6.3.2.2. Effects of Different Treatments on Oral Glucose Tolerance, Fasting Insulin, HOMA-IR and gene expression of Insulin Receptor……...156

6.3.2.3. Effects of Different Treatments on Lipid Profile……..159

6.3.3. Effects of Different Treatments on Reproductive parameters…….160

6.3.3.1. Effects of Different Treatments on Estrus Cyclicity……160

6.3.3.2. Effects of Different Treatments on Ovarian Histology……161

6.3.3.3. Effects of Different Treatments on Hormone Profile……...162

6.3.3.4. Effects of Different Treatments on Gonadotropin Receptors……...164

6.3.3.5. Effect of Different Treatments on Steroid Receptors……165

6.3.3.6. Effect of Different Treatment on Key Steroid Markers……166

6.3.4. Quantitative Analysis of LP1 and LP3 in plasma and ovaries of Letrozole induced PCOS mice…….……168

6.3.5 Effect of Different Treatment on Toxicity parameters…….168

6.4. Discussion……...172

6.5. Conclusion……...178

Chapter 7. Summary……...180

Chapter 8. Bibliography…….……190

Synopsis

Publications and citations